Summary
This filing is an amendment to a previous 8-K and primarily addresses changes in Becton, Dickinson and Company's (BDX) executive leadership, specifically the CFO transition and the retirement of the current CFO, Christopher Reidy. The key takeaway for investors is the planned succession of the Chief Financial Officer role, with Christopher DelOrefice stepping into the position effective September 6, 2021. This transition is accompanied by a phased retirement plan for Mr. Reidy, who will remain with the company in a Chief Administrative Officer capacity until his full retirement by March 31, 2022. His continued involvement is critical for overseeing information technologies, global shared services, and, importantly, leading the spin-off of BDX's Diabetes Care business.
Key Highlights
- 1Christopher DelOrefice appointed as Executive Vice President and Chief Financial Officer, effective September 6, 2021, succeeding Christopher Reidy.
- 2Current CFO, Christopher Reidy, will transition to Executive Vice President and Chief Administrative Officer until his retirement.
- 3Mr. Reidy's retirement is scheduled for no later than March 31, 2022, following the execution of the Diabetes Care business spin-off.
- 4Mr. Reidy will play a key role in managing the spin-off of the Diabetes Care business into an independent company.
- 5Mr. Reidy's compensation is adjusted during the transition period, with a reduced base salary and bonus target from January 1, 2022.
- 6Mr. Reidy's annual equity-based compensation award for November 2021 will be significantly reduced from $3.3 million to $700,000.
- 7The spin-off of the Diabetes Care business remains subject to customary conditions, including board and regulatory approvals.